NBP logo

NOVABRIDGE BIOSCIENCES

NBPNASDAQ
🏆 #3779 by market capUS Equity
$1.26▲ $0.01 (+1.20%)
Latest quote
🔔
Track NBP
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.2%
7d▼ 5.3%
14d▼ 3.4%
30d▼ 8.4%
ytd▼ 68.3%
1y▼ 72.8%
🏦Market Cap
$341M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
100.0%
High
💵FCF Margin
—
⚖️P/S Ratio
3.1x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.26 – $1.27
52-Week Range
$1.19 – $5.19
Volume (shares)
1,131
Avg Volume (shares)
—
Shares Outstanding
270.7M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
3.1x
EPS (TTM)
$-0.19
Dividend Yield
—
Dilution (1yr)
−38.4%
NBP logo

NOVABRIDGE BIOSCIENCES

NBP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −96.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▼ −94.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
50.2M▼ −38.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$30M▼ −$440M YoY
StockOtter · stockotter.space

About NOVABRIDGE BIOSCIENCES

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.